Last update 14 Jun 2025

Recombinant Saccharomyces cerevisiae-CEA(GlobeImmune)

Overview

Basic Info

Drug Type
Recombinant vector vaccine, Therapeutic vaccine
Synonyms
Recombinant Saccharomyces cerevisiae-CEA (610D), GI 6207, GI-6207
Target
CEA
Action
inhibitors
Mechanism
CEA inhibitors(Carcinoembryonic antigen inhibitors)
Therapeutic Areas
NeoplasmsDigestive System DisordersEndocrinology and Metabolic Disease+ [3]
Active Indication-
Inactive Indication
Metastatic Colorectal CarcinomaMetastatic Pancreatic CancerNon-Small Cell Lung Cancer+ [8]
Originator Organization
GlobeImmune, Inc.GlobeImmune, Inc.
Active Organization-
Inactive Organization
ImmunityBio, Inc.ImmunityBio, Inc.GlobeImmune, Inc.GlobeImmune, Inc.NantKwest, Inc.NantKwest, Inc.
License Organization
Celgene Corp.Celgene Corp.GlobeImmune, Inc.GlobeImmune, Inc.
Drug Highest PhaseDiscontinuedPhase 2
First Approval Date-
Regulation-
Login to view timeline

Related

15
Clinical Trials associated with Recombinant Saccharomyces cerevisiae-CEA(GlobeImmune)
NCT03563157
/ TerminatedPhase 1/2
NANT Colorectal Cancer (CRC) Vaccine: A Phase 1b/2 Trial of the NANT CRC Vaccine vs Regorafenib in Subjects With Metastatic CRC Who Have Been Previously Treated With Standard-of-Care Therapy
NCT03554109
/ WithdrawnPhase 2
An Open-Label Randomized Phase 2 Trial Of The NANT NEOADJUVANT Triple-Negative Breast Cancer (TNBC) VACCINE VS Standard-Of-Care For The Neoadjuvant Treatment Of Subjects With TNBC
NCT03169777
/ WithdrawnPhase 1/2
NANT Colorectal Cancer (CRC) Vaccine: Combination Immunotherapy in Subjects With Recurrent or Metastatic CRC
100 Clinical Results associated with Recombinant Saccharomyces cerevisiae-CEA(GlobeImmune)
Login to view more data
100 Translational Medicine associated with Recombinant Saccharomyces cerevisiae-CEA(GlobeImmune)
Login to view more data
100 Patents (Medical) associated with Recombinant Saccharomyces cerevisiae-CEA(GlobeImmune)
Login to view more data
100 Deals associated with Recombinant Saccharomyces cerevisiae-CEA(GlobeImmune)
Login to view more data

R&D Status

10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Metastatic Colorectal CarcinomaPhase 2
United States
ImmunityBio, Inc.ImmunityBio, Inc.
28 Sep 2018
Triple Negative Breast CancerPhase 2
United States
ImmunityBio, Inc.ImmunityBio, Inc.
01 Sep 2018
Metastatic Pancreatic CancerPhase 2
United States
ImmunityBio, Inc.ImmunityBio, Inc.
01 Aug 2018
Unresectable Hepatocellular CarcinomaPhase 2
United States
ImmunityBio, Inc.ImmunityBio, Inc.
25 May 2018
Non-Small Cell Lung CancerPhase 2-
ImmunityBio, Inc.ImmunityBio, Inc.
01 Feb 2018
Squamous Cell CarcinomaPhase 2
United States
NantKwest, Inc.NantKwest, Inc.
13 Jan 2018
Squamous Cell Carcinoma of Head and NeckPhase 2-
ImmunityBio, Inc.ImmunityBio, Inc.
01 Dec 2017
Transitional Cell CarcinomaPhase 2-
ImmunityBio, Inc.ImmunityBio, Inc.
01 Dec 2017
Unresectable MelanomaPhase 2-
ImmunityBio, Inc.ImmunityBio, Inc.
01 Dec 2017
Thyroid CancerPhase 2
United States
GlobeImmune, Inc.GlobeImmune, Inc.
26 Apr 2013
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
NCT03563157 (CTgov)
Phase 1/2
Metastatic Colorectal Carcinoma
2
(NANT Colorectal Cancer (CRC) Vaccine)
sdbjyvsjow = yzmiqhuhtr slyevqodkp (poajqpduwv, quudwhgqmo - yurqejsrrx)
View more
-
11 Dec 2024
(Regorafenib)
zvpvqbstgx(pxmmofemwd) = nnctayfuqj oddennondb (bzokpkuwqo, ozrckacqrf - ofbnurlgql)
View more
NCT01856920 (QUILT-3.006, CTgov)
Phase 2
Thyroid Cancer, Medullary
35
(Surveillance Subjects)
fowiyfxgrd = sfdebnfybl hkifsvacya (vhntuseonp, vejuwyuqkm - sptxrfwwbm)
View more
-
09 Jul 2024
CEA (610D)+GI-6207
(Vaccine Subjects)
fowiyfxgrd = jhqclnrdiu hkifsvacya (vhntuseonp, usgzmsaxpr - owkfiwboyz)
View more
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
login
or
view full example data
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
login
or
view full example data
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
login
or
view full example data
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
login
or
view full example data
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
login
or
view full example data
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
login
or
view full example data
Understand key drug designations in just a few clicks with Synapse.
AI Agents Built for Biopharma Breakthroughs
Accelerate discovery. Empower decisions. Transform outcomes.
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free